Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Crohns Colitis ; 6(6): 698-707, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22398098

ABSTRACT

BACKGROUND AND AIMS: Therapeutic drug monitoring of active metabolites of thiopurines, azathioprine and 6-mercaptopurine, is relatively new. The proposed therapeutic threshold level of the active 6-thioguanine nucleotides (6-TGN) is ≥235 pmol/8×10(8) erythrocytes. The aim of this prospective cross-sectional study was to compare 6-TGN levels in adult thiopurine tolerant IBD patients with an exacerbation with those in remission, and to determine the therapeutic 6-TGN cut-off level. METHODS: Hundred IBD patients were included. Outcome measures were thiopurine metabolite levels, calculated therapeutic 6-TGN cut-off level, CDAI/CAI scores, thiopurine dose and TPMT enzyme activity. RESULTS: Forty-one patients had an exacerbation, 59 patients were in remission. In 17% of all patients 6-TGN levels were compatible with non-compliance. The median 6-TGN levels were not significantly different between the exacerbation and remission group (227 versus 263 pmol/8×10(8) erythrocytes, p=0.29). The previous reported therapeutic 6-TGN cut-off level of 235 pmol/8×10(8) erythrocytes was confirmed in this study. Twenty-six of the 41 patients (63%) with active disease had 6-TGN levels below this threshold and 24 of 59 IBD patients (41%) in clinical remission (p=0.04). CONCLUSIONS: Thiopurine non-compliance occurs frequently both in active and quiescent disease. 6-TGN levels below or above the therapeutic threshold are associated with a significant higher chance of IBD exacerbation and remission, respectively. These data support the role of therapeutic drug monitoring in thiopurine maintenance therapy in IBD to reveal non-compliance or underdosing, and can be used as a practical tool to optimize thiopurine therapy, especially in case of thiopurine non-response.


Subject(s)
Azathioprine/therapeutic use , Drug Monitoring , Guanine Nucleotides/blood , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Mercaptopurine/therapeutic use , Thioinosine/analogs & derivatives , Thionucleotides/blood , Adolescent , Adult , Aged , Azathioprine/metabolism , Biomarkers, Pharmacological/blood , Chromatography, High Pressure Liquid , Cross-Sectional Studies , Disease Progression , Dose-Response Relationship, Drug , Female , Genetic Markers , Humans , Immunosuppressive Agents/metabolism , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/metabolism , Maintenance Chemotherapy , Male , Medication Adherence/statistics & numerical data , Mercaptopurine/metabolism , Methyltransferases/genetics , Methyltransferases/metabolism , Middle Aged , Prospective Studies , Severity of Illness Index , Thioinosine/blood , Young Adult
2.
Cancer Prev Res (Phila) ; 4(10): 1563-71, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21750209

ABSTRACT

Given the current increase in colorectal cancer screening, information on performance of screening tests is needed, especially in groups with a presumed lower test performance. We compared test performance of immunologic fecal occult blood testing (FIT) and pseudosigmoidoscopy with colonoscopy for detection of advanced adenomas in an average risk screening population. In addition, we explored the influence of gender, age, and location on test performance. FIT was collected prior to colonoscopy with a 50 ng/mL cutoff point. FIT results and complete colonoscopy findings were available from 329 subjects (mean age: 54.6 ± 3.7 years, 58.4% women). Advanced adenomas were detected in 38 (11.6%) of 329 subjects. Sensitivity for advanced adenomas of FIT and sigmoidoscopy were 15.8% (95% CI: 6.0-31.3) and 73.7% (95% CI: 56.9-86.6), respectively. No sensitivity improvement was obtained using the combination of sigmoidoscopy and FIT. Mean fecal hemoglobin in FIT positives was significantly lower for participants with only proximal adenomas versus those with distal ones (P = 0.008), for women versus men (P = 0.023), and for younger (<55 years) versus older (≥55 years) subjects (P = 0.029). Sensitivities of FIT were 0.0% (95% CI: 0.0-30.9) in subjects with only proximal versus 21.4% (95% CI: 8.3-41.0) in those with distal nonadvanced adenomas; 5.3% (95% CI: 0.0-26.0) in women versus 26.3% (95% CI: 9.2-51.2) in men; 9.5% (95% CI: 1.2-30.4) in younger versus 23.5% (95% CI: 6.8-49.9) in older subjects. Sigmoidoscopy had a significantly higher sensitivity for advanced adenomas than FIT. A single FIT showed very low sensitivity, especially in subjects with only proximal nonadvanced adenomas, in women, and in younger subjects. This points to the existence of "low" FIT performance in subgroups and the need for more tailored screening strategies.


Subject(s)
Adenoma/prevention & control , Colonoscopy , Colorectal Neoplasms/prevention & control , Mass Screening , Occult Blood , Sigmoidoscopy , Adenoma/diagnosis , Aged , Cohort Studies , Colorectal Neoplasms/diagnosis , Early Detection of Cancer , Female , Humans , Immunologic Tests , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity
3.
Scand J Gastroenterol ; 45(12): 1449-56, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20653489

ABSTRACT

OBJECTIVE: The European Panel on the Appropriateness of Crohn's disease Therapy (EPACT) has developed appropriateness criteria. We have applied these criteria retrospectively to the population-based inception cohort of Crohn's disease (CD) patients of the European Collaborative Study Group on Inflammatory Bowel Disease (EC-IBD). MATERIAL AND METHODS: A total of 426 diagnosed CD patients from 13 European centers were enrolled at the time of diagnosis (first flare, naive patients). We used the EPACT definitions to identify 247 patients with active luminal CD. We then assessed the appropriateness of the initial drug prescription according to the EPACT criteria. RESULTS: Among the cohort patients 163 suffered from mild-to-moderate CD and 84 from severe CD. Among the mild-to-moderate disease group, 96 patients (59%) received an appropriate treatment, whereas for 66 patients (40%) the treatment was uncertain and in one case (1%) inappropriate. Among the severe disease group, 86% were treated medically and 14% required surgery. 59 (70%) were appropriately treated, whereas for one patient (1%) the procedure was considered uncertain and for 24 patients (29%) inappropriate. CONCLUSION: Initial treatment was appropriate in the majority of cases for non-complicated luminal CD. Inappropriate or uncertain treatment was given in a significant minority of patients, with an increased potential risk of adverse events.


Subject(s)
Crohn Disease/diagnosis , Crohn Disease/therapy , Guideline Adherence , Quality Assurance, Health Care , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Europe , Female , Humans , Male , Middle Aged , Practice Patterns, Physicians' , Retrospective Studies
4.
Curr Colorectal Cancer Rep ; 6(1): 44-47, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20157367

ABSTRACT

In the past four decades, chemoprevention of colorectal cancer (CRC) has been the subject of many epidemiologic and intervention trials of naturally occurring or pharmacologic agents. Recently, the positioning of cyclooxygenase 2 inhibitors as a viable option in this context was a major breakthrough; however, it was hampered by adverse cardiovascular events. This review questions whether chemopreventive measures for CRC are ready to be used in mass or individual applications, standing alone or in combination with other CRC-preventive measures. It also discusses steps that may be undertaken to explore this field further.

5.
J Psychosom Res ; 68(3): 295-302, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20159217

ABSTRACT

OBJECTIVE: Although there is a suggestion that the medical psychiatric unit (MPU) may reduce length of hospital stay (LOS), little is known about costs in terms of medical service use and psychiatric interventions in MPU care. METHOD: A record linkage study was conducted, linking cost data of hospital medical service use, LOS, and hospital psychiatric interventions to patients admitted to the MPU of the Maastricht University Medical Centre (MUMC) between 1998 and 2004. The data set was analyzed to enable comparison between cost changes of the same complex patient population following either MPU index admission or index admissions to reference MUMC medical wards. RESULTS: Comparisons revealed lower costs of medical service use in favor of the MPU (-euro104; 95% CI -euro174 to -euro35; P<.01). However, cost of psychiatric intervention and cost of LOS were higher after MPU admission (respectively, +euro165; 95% CI +euro25 to +euro305; P<.05; and +euro202; 95% CI +euro170 to +euro235; P<.001). Total costs were higher after MPU admission compared to medical ward admission (+euro263; 95% CI +euro68 to +euro458; P<.05). These differences were not moderated by somatic diagnosis or previous pattern of admissions. CONCLUSION: The findings suggest that patients at the interface of psychiatric and somatic morbidity are diagnosed and treated adequately at the MPU, leading to a decrease in medical service use and an appropriate increase in exposure to psychiatric interventions. These results are specifically generalizable to MPUs with a focus on psychosomatic conditions, for instance, somatoform disorders or affective disorders with comorbid somatic diseases. However, failure to show cost savings in terms of LOS compared to medical wards outweighs cost-benefit derived from lower medical service use, suggesting that MPU activities may gain in cost-effectiveness if shifted more to outpatient psychosomatic care solutions.


Subject(s)
Health Care Costs , Hospitals, University/economics , Length of Stay/economics , Length of Stay/statistics & numerical data , Mental Disorders/economics , Mental Disorders/rehabilitation , Mental Health Services/economics , Mental Health Services/statistics & numerical data , Psychiatric Department, Hospital/economics , Psychophysiologic Disorders/economics , Psychophysiologic Disorders/rehabilitation , Adolescent , Adult , Costs and Cost Analysis , Female , Health Services/economics , Health Services/statistics & numerical data , Health Status , Hospitalization , Humans , Male , Middle Aged , Netherlands/epidemiology , Young Adult
6.
Cancer Res ; 69(11): 4691-9, 2009 Jun 01.
Article in English | MEDLINE | ID: mdl-19435926

ABSTRACT

We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma/diagnosis , Colorectal Neoplasms/diagnosis , DNA Methylation , Feces/chemistry , Glycoproteins/genetics , Aged , Aged, 80 and over , Algorithms , Biomarkers, Tumor/analysis , Caco-2 Cells , Carcinoma/genetics , Carcinoma/pathology , Case-Control Studies , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , DNA Methylation/physiology , DNA Mutational Analysis/methods , Early Detection of Cancer , Female , Glycoproteins/analysis , HCT116 Cells , HT29 Cells , Humans , Male , Middle Aged , Pilot Projects , Tumor Cells, Cultured
7.
J Crohns Colitis ; 3(2): 115-24, 2009 Jun.
Article in English | MEDLINE | ID: mdl-21172254

ABSTRACT

BACKGROUND AND AIMS: Increasing incidence in Inflammatory Bowel Disease (IBD) has been suggested. Recent data on population based incidence rates within Europe are however scarce. Primary aim was to investigate prospectively the incidence of IBD within a well-defined geographical and administrative area of the Netherlands, the South Limburg IBD registry. Secondary aims were to study the duration of symptoms before diagnosis (lag time) and seasonal influences on the incidence of IBD. METHODS: The incidence was examined using standardized registration of all newly diagnosed IBD patients, between 1-1-1991 and 1-1-2003. Medical records were reviewed to verify the diagnosis. At inclusion, diagnostic lag time was registered in months. RESULTS: Age standardized incidence rates per 100,000 person-years (p-y) were: Crohn's Disease, male 4.84, female 7.58; Ulcerative Colitis, male 8.51, female 6.92; and Indeterminate Colitis, male 1.05, female 0.93. Incidence rates did not significantly changes over time in either Crohn's Disease, Ulcerative Colitis or Indeterminate Colitis. Lag time was 5 (0-360) months in Crohn's Disease, 3.0 (0-480) months in Ulcerative Colitis and 3.0 (0-180) months in Indeterminate Colitis. Lag time was not significantly different between the periods 1991-1993 and 2000-2002, and no statistical differences in the onset of symptoms per calendar month or season were found. CONCLUSIONS: Our results, from the South Limburg region (the Netherlands), show no significant change in incidence rates of IBD. The incidence found is relatively high compared to other European countries. Lag time did not change during the study period, and seasonal influence of incidence rates could not be confirmed.

8.
Eur J Gastroenterol Hepatol ; 20(8): 740-7, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18617778

ABSTRACT

BACKGROUND: Earlier studies have documented that the prevalence of decreased bone mineral density (BMD) is elevated in patients with inflammatory bowel disease. The objective of this study was to investigate the prevalence of vertebral deformities in inflammatory bowel disease patients and their relation with BMD and bone turnover. METHODS: One hundred and nine patients with Crohn's disease (CD) and 72 with ulcerative colitis (UC) (age 44.5+/-14.2 years) were studied. BMD of the hip (by dual X-ray absorptiometry) was measured and a lateral single energy densitometry of the spine for assessment of vertebral deformities was performed. Serum markers of bone resorption (carboxy-terminal cross-linked telopeptide of type I collagen) and formation (procollagen type I amino-terminal propeptide) were measured, and determinants of prevalent vertebral deformities were assessed using logistic regression analysis. RESULTS: Vertebral deformities were found in 25% of both CD and UC patients. Comparing patients with and without vertebral deformities, no significant difference was found between Z-scores and T-scores of BMD, or levels of serum carboxy-terminal cross-linked telopeptide of type I collagen and serum procollagen type I amino-terminal propeptide. Using logistic regression analysis the only determinant of any morphometric vertebral deformity was sex. The presence of multiple vertebral deformities was associated with older age and glucocorticoid use. CONCLUSION: The prevalence of morphometric vertebral deformities is high in CD and UC. Male sex, but neither disease activity, bone turnover markers, clinical risk factors, nor BMD predicted their presence. The determinants for having more than one vertebral deformity were age and glucocorticoid use. This implies that in addition to screening for low BMD, morphometric assessment of vertebral deformities is warranted in CD and UC.


Subject(s)
Inflammatory Bowel Diseases/complications , Spinal Fractures/etiology , Absorptiometry, Photon , Adult , Bone Density , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/physiopathology , Bone Resorption/etiology , Bone Resorption/physiopathology , Colitis, Ulcerative/complications , Crohn Disease/complications , Cross-Sectional Studies , Female , Hip Fractures/etiology , Hip Fractures/physiopathology , Humans , Male , Middle Aged , Spinal Curvatures/etiology , Spinal Curvatures/physiopathology , Spinal Fractures/physiopathology
9.
J Crohns Colitis ; 2(2): 114-22, 2008 Jun.
Article in English | MEDLINE | ID: mdl-21172201

ABSTRACT

OBJECTIVES: Perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) have been proposed as markers for diagnosis and for subtyping of inflammatory bowel disease (IBD). The aim of this study was to investigate the association of p-ANCA and ASCA with a 10-year disease outcome in terms of cumulative rate of colectomy and relapse in a population-based European inception cohort of ulcerative colitis (UC) patients. METHODS: Serum samples from 432 consenting patients were analysed for p-ANCA and ASCA. The results were compared with the cumulative colectomy rate, relapsing disease and total number of relapses. We used multiple regression analyses adjusted for age, sex, residence, disease extent at diagnosis, smoking, familial IBD and drug treatment to study the relationship between serological values and disease course. RESULTS: The relapse rate was higher in the p-ANCA-positive patients: 82% (95% confidence interval [CI] 75-89%) compared with 67% (CI 62-72%, p=0.011) in the p-ANCA-negative patients. The risk of relapsing disease course was higher by a factor of 1.4 (CI 1.1-1.8, p=0.009) for p-ANCA-positive patients than for p-ANCA-negative patients, and the corresponding relative risk (RR) for the total number of relapses was 1.9 (CI 1.7-2.1, p<0.001). In ASCA-positive patients RR for the total number of relapses was 1.8 (CI 1.5-2.1, p<0.001). No significant association with colectomy rate was found for the presence of either p-ANCA or ASCA. CONCLUSION: UC patients positive for p-ANCA and possibly for ASCA may have a more unfavourable long-term disease outcome in terms of relapse than UC patients without these markers.

10.
Am J Gastroenterol ; 103(1): 178-89, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17900321

ABSTRACT

BACKGROUND: One of the side effects of antimicrobial therapy is a disturbance of the intestinal microbiota potentially resulting in antibiotic-associated diarrhea (AAD). In this placebo-controlled double-blind study, the effect of a multispecies probiotic on the composition and metabolic activity of the intestinal microbiota and bowel habits was studied in healthy volunteers taking amoxycillin. METHODS: Forty-one healthy volunteers were given 500 mg amoxycillin twice daily for 7 days and were randomized to either 5 g of a multispecies probiotic, Ecologic AAD (10(9) cfu/g), or placebo, twice daily for 14 days. Feces and questionnaires were collected on day 0, 7, 14, and 63. Feces was analyzed as to the composition of the intestinal microbiota, and beta-glucosidase activity, endotoxin concentration, Clostridium difficile toxin A, short chain fatty acids (SCFAs), and pH were determined. Bowel movements were scored according to the Bristol stool form scale. RESULTS: Mean number of enterococci increased significantly from log 4.1 at day 0 to log 5.8 (day 7) and log 6.9 (day 14) cfu/g feces (P < 0.05) during probiotic intake. Although no other significant differences were observed between both intervention groups, within each group significant changes were found over time in both microbial composition and metabolic activity. Moreover, bowel movements with a frequency >or=3 per day for at least 2 days and/or a consistency >or=5 for at least 2 days were reported less frequently in the probiotic compared to the placebo group (48%vs 79%, P < 0.05). CONCLUSIONS: Apart from an increase in enterococci no significant differences in microbial composition and metabolic activity were observed in the probiotic compared with the placebo group. However, changes over time were present in both groups, which differed significantly between the probiotic and the placebo arm, suggesting that the amoxycillin effect was modulated by probiotic intake. Moreover, the intake of a multispecies probiotic significantly reduced diarrhea-like bowel movements in healthy volunteers receiving amoxycillin.


Subject(s)
Amoxicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Intestines/microbiology , Probiotics/pharmacology , Adolescent , Adult , Aged , Bacteria/growth & development , Bacteria/isolation & purification , Colony Count, Microbial , Defecation/drug effects , Double-Blind Method , Female , Follow-Up Studies , Humans , Intestines/physiology , Male , Middle Aged , Prognosis , Reference Values , beta-Glucosidase/metabolism
11.
Scand J Gastroenterol ; 42(10): 1151-7, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17852876

ABSTRACT

OBJECTIVE: The assessment of intestinal inflammation in patients with inflammatory bowel disease (IBD) remains a difficult challenge. Both rectal nitric oxide (NO) and fecal calprotectin can be measured using non-invasive methods and are emerging as promising inflammatory markers in IBD. In this study the aim was to compare calprotectin and NO levels in IBD patients. MATERIAL AND METHODS: Rectal NO was measured tonometrically in 23 healthy volunteers and 32 patients with IBD. In addition, we collected stool samples from all subjects for measurement of fecal calprotectin and nitrate/nitrite (NO metabolites). RESULTS: Patients with IBD had greatly increased NO and calprotectin levels compared to healthy volunteers (p <0.001). In addition, the nitrate levels were slightly increased in IBD patients. A weak correlation was found between rectal NO levels, disease activity and number of loose stools in IBD patients (Spearman's rho 0.37 and 0.51, respectively; p <0.05). Fecal calprotectin correlated only with age (Spearman's rho 0.51; p <0.01). However, no correlation was found between NO and calprotectin. CONCLUSIONS: Both rectal NO and fecal calprotectin are greatly increased during bowel inflammation, but they may reflect different parts of the inflammatory process. Future studies will elucidate the clinical usefulness of these two markers.


Subject(s)
Crohn Disease/diagnosis , Feces/chemistry , Inflammatory Bowel Diseases/diagnosis , Leukocyte L1 Antigen Complex/analysis , Nitric Oxide/analysis , Biomarkers/analysis , Humans , Netherlands , Nitrates/analysis , Nitrites/analysis , Reference Values
12.
Scand J Gastroenterol ; 42(3): 333-44, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17354113

ABSTRACT

OBJECTIVE: Geographic differences in disease course of Crohn's disease (CD) might possibly be related to differences in genetic and environmental factors encountered in different parts of the world. The aim of this study was to assess differences in treatment regimens within a European cohort of CD patients as a reflection of disease course, and to identify associated phenotypic risk factors at diagnosis. MATERIAL AND METHODS: A prospective European population-based inception cohort of 380 CD patients was studied. The patients were classified for phenotype according to the Vienna classification. Differences between Northern and Southern European centres in treatment over the first 10 years of disease were analysed using a competing risks survival analysis method. RESULTS: Patients in the North were more likely to have had surgery (p<0.01), whereas patients in the South were more likely to have been treated medically (p<0.01). Phenotype at diagnosis was not predictive of differences in treatment regimens between North and South. CONCLUSIONS: In this study, a difference in management of CD was observed between Northern and Southern European centres. This suggests that there may be a North-South disease severity gradient across Europe. Phenotypic differences between patients in the North and South did not explain this observed difference.


Subject(s)
Crohn Disease/epidemiology , Adult , Age Distribution , Age Factors , Confounding Factors, Epidemiologic , Crohn Disease/drug therapy , Crohn Disease/genetics , Europe/epidemiology , Female , Follow-Up Studies , Health Transition , Humans , Male , Phenotype , Predictive Value of Tests , Proportional Hazards Models , Prospective Studies , Risk Factors , Severity of Illness Index , Sex Distribution , Sex Factors , Survival Analysis
13.
J Thromb Thrombolysis ; 24(2): 175-82, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17308963

ABSTRACT

BACKGROUND: In ulcerative colitis (UC), a state of hypercoagulation has frequently been observed. Low molecular weight heparin (LMWH) has shown beneficial effects as an adjuvant treatment of steroid refractory UC in open trials. We assessed potential therapeutic effects of the LMWH reviparin in hospitalised patients with mesalazine refractory UC, as well as its influence on haemostasis factors. METHODS: Twenty-nine patients with mild-to-moderately active UC were included in a double-blind placebo controlled trial. All patients had a flare-up of disease under mesalazine treatment. Reviparin (Clivarin) 3,436 IU anti-Xa/0.6 ml or placebo s.c. was added, and self-administered twice daily for 8 weeks. Patients were monitored for possible adverse events and changes in clinical symptoms. Endoscopical, histological, biochemical and haemostasis parameters were analysed. RESULTS: Tolerability and compliance were excellent and no serious adverse events occurred. No significant differences were observed on the clinical, endoscopical and histological outcome, as compared to placebo. A high intrinsic and extrinsic thrombin potential was found before LMWH therapy. However, the significant reduction in the thrombin generation by LMWH was not related to the reduction in disease activity. CONCLUSION: The LMWH reviparine reduces thrombin generation in patients with mild-to-moderately active, mesalazine refractory UC, but is not associated with a reduction in disease activity.


Subject(s)
Colitis, Ulcerative/drug therapy , Heparin, Low-Molecular-Weight/administration & dosage , Mesalamine/pharmacology , Salvage Therapy/methods , Thrombin/drug effects , Thrombophilia/drug therapy , Adult , Double-Blind Method , Female , Hemostasis/drug effects , Heparin, Low-Molecular-Weight/pharmacology , Humans , Male , Patient Compliance , Self Care , Thrombin/biosynthesis , Treatment Outcome
14.
Gastroenterology ; 132(2): 507-15, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17258717

ABSTRACT

BACKGROUND & AIMS: The colectomy rate in ulcerative colitis (UC) is related to morbidity and to treatment decisions made during disease course. The aims of this study were to determine the colectomy risk in UC in the first decade after diagnosis and to identify factors that may influence the choice of surgical treatment. METHODS: In 1991-1993, 781 UC patients from 9 centers located in 7 countries in northern and southern Europe and in Israel were included in a prospective inception cohort study. After 10 years of follow-up, 617 patients had complete medical records, 73 had died, and 91 had been lost to follow-up. RESULTS: There were no significant differences in age, sex, or disease extent at diagnosis between patients followed for 10 years and those lost to follow-up. The 10-year cumulative risk of colectomy was 8.7%: 10.4% in the northern and 3.9% in the southern European centers (P < .001). Colectomy was more likely in extensive colitis than in proctitis, with an adjusted hazard ratio (HR) of 4.1 (95% CI: 2.0-8.4). Compared with the southern centers, the adjusted HR was 2.7 (95% CI: 1.3-5.6) for The Netherlands and Norway together and 8.2 (95% CI: 3.6-18.6) for Denmark. Age at diagnosis, sex, and smoking status at diagnosis had no statistically significant influence on colectomy rates. CONCLUSIONS: The colectomy rate was found to be lower than that in previous publications, but there was a difference between northern and southern Europe. Colectomy was associated with extensive colitis, but the geographic variations could not be explained.


Subject(s)
Colectomy/statistics & numerical data , Colitis, Ulcerative/surgery , Patient Selection , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Colectomy/methods , Colitis, Ulcerative/etiology , Colitis, Ulcerative/pathology , Drug-Related Side Effects and Adverse Reactions , Europe , Female , Follow-Up Studies , Humans , Israel , Male , Middle Aged , Proportional Hazards Models , Prospective Studies , Residence Characteristics/statistics & numerical data , Risk Factors , Severity of Illness Index , Smoking/adverse effects , Time Factors
15.
Scand J Gastroenterol Suppl ; (243): 46-54, 2006.
Article in English | MEDLINE | ID: mdl-16782622

ABSTRACT

OBJECTIVE: To give a general outline of a 10-year clinical follow-up study of a population-based European cohort of inflammatory bowel disease (IBD) patients and to present the first results in terms of clinical outcome parameters and risk factors. MATERIALS AND METHODS: A population-based cohort of newly, prospectively, diagnosed cases was initiated between 1991 and 1993. The 2201 patients with IBD (706 had Crohn's disease (CD), 1379 had ulcerative colitis (UC) and 116 had indeterminate colitis) originated from 20 different areas in 11 different European countries and Israel. For the 10-year follow-up of this cohort, electronic data-collecting instruments were made available through an Internet-based website. Data concerning vital status, disease activity, medication use, surgical events, cancer, pregnancy, fertility, quality of life and health-care costs were gathered. A blood sample was obtained from patients and controls to perform genotypic characterization. RESULTS: Thirteen centres from eight European countries and Israel participated. In 958 (316 CD and 642 UC) out of a total of 1505 IBD patients (64%) from these 13 centres, a complete dataset was obtained at follow-up. Even though an increased mortality risk was observed in CD patients 10 years after diagnosis, a benign disease course was observed in this patient group in terms of disease recurrence. A correlation between ASCA and CARD15 variants in CD patients and complicated disease course was observed. A north-south gradient was observed regarding colectomy rates in UC patients. Direct costs were found to be highest in the first year after diagnosis and greater in CD patients than in UC patients, with marked differences between participating countries. CONCLUSIONS: This 10-year clinical follow-up study of a population-based European cohort of IBD patients provides updated information on disease outcome of these patient groups.


Subject(s)
Colitis, Ulcerative/epidemiology , Crohn Disease/epidemiology , Adult , Artificial Intelligence , Colectomy , Colitis, Ulcerative/economics , Colitis, Ulcerative/genetics , Colitis, Ulcerative/surgery , Communication , Crohn Disease/economics , Crohn Disease/genetics , Crohn Disease/surgery , Europe/epidemiology , Female , Follow-Up Studies , Genotype , Health Care Costs , Humans , Internet , Israel/epidemiology , Male , Nod2 Signaling Adaptor Protein/genetics , Phenotype , Physician-Patient Relations , Polymorphism, Genetic , Prospective Studies , Recurrence , Risk Factors
16.
Clin Gastroenterol Hepatol ; 3(2): 113-21, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15704045

ABSTRACT

BACKGROUND & AIMS: Osteoporosis frequently occurs in Crohn's disease, often because of corticosteroids. Budesonide as controlled release capsules is a locally acting corticosteroid with low systemic bioavailability. We investigated its effects on bone compared with prednisolone. METHODS: In 34 international centers, 272 patients with Crohn's disease involving ileum and/or colon ascendens were randomized to once daily treatment with budesonide or prednisolone for 2 years at doses adapted to disease activity. One hundred eighty-one corticosteroid-free patients had active disease (98 had never received corticosteroids, corticosteroid naive; 83 had received corticosteroids previously, corticosteroid exposed), and 90 had quiescent disease, receiving long-term low doses of corticosteroids, corticosteroid-dependent; in 1 patient, no efficacy data were obtained. Bone mineral density and fractures were assessed in a double-blinded fashion; disease activity, side effects, and quality of life were monitored. RESULTS: Neither the corticosteroid-free nor the corticosteroid-dependent patients treated with budesonide differed significantly in bone mineral density from those receiving prednisolone. However, corticosteroid-naive patients receiving budesonide had smaller reductions in bone mineral density than those on prednisolone (mean, -1.04% vs -3.84%; P = .0084). Treatment-emergent corticosteroid side effects were less frequent with budesonide. Efficacy was similar in both groups. CONCLUSIONS: Treatment with budesonide is associated with better preserved bone mass compared with prednisolone in only the corticosteroid-naive patients with active ileocecal Crohn's disease. In both the corticosteroid-free and corticosteroid-dependent groups, budesonide and prednisolone were equally effective for up to 2 years, but budesonide caused fewer corticosteroid side effects.


Subject(s)
Budesonide/adverse effects , Crohn Disease/drug therapy , Osteoporosis/chemically induced , Prednisolone/adverse effects , Administration, Oral , Adult , Aged , Analysis of Variance , Bone Density/drug effects , Budesonide/therapeutic use , Crohn Disease/diagnosis , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Osteoporosis/physiopathology , Prednisolone/therapeutic use , Probability , Reference Values , Risk Assessment , Severity of Illness Index , Single-Blind Method
17.
World J Gastroenterol ; 11(45): 7152-8, 2005 Dec 07.
Article in English | MEDLINE | ID: mdl-16437663

ABSTRACT

AIM: To describe an Internet-based data acquisition facility for a European 10-year clinical follow-up study project of a population-based cohort of inflammatory bowel disease (IBD) patients and to investigate the influence of demographic and disease related patient characteristics on response rates. METHODS: Thirteen years ago, the European Collaborative study group of IBD (EC-IBD) initiated a population-based prospective inception cohort of 2 201 uniformly diagnosed IBD patients within 20 well-described geographical areas in 11 European countries and Israel. For the 10-year follow-up of this cohort, an electronic patient questionnaire (ePQ) and electronic physician per patient follow-up form (ePpPFU) were designed as two separate data collecting instruments and made available through an Internet-based website. Independent demographic and clinical determinants of ePQ participation were analyzed using multivariate logistic regression. RESULTS: In 958 (316 CD and 642 UC) out of a total number of 1 505 (64%) available IBD patients, originating from 13 participating centers from nine different countries, both ePQ and ePpPFU were completed. Patients older than 40 years at ePQ completion (OR: 1.53 (95%CI: 1.14-2.05)) and those with active disease during the 3 mo previous to ePQ completion (OR: 3.32 (95%CI: 1.57-7.03)) were significantly more likely to respond. CONCLUSION: An Internet-based data acquisition tool appeared successful in sustaining a unique Western-European and Israelian multi-center 10-year clinical follow-up study project in patients afflicted with IBD.


Subject(s)
Inflammatory Bowel Diseases , Adult , Cohort Studies , Data Interpretation, Statistical , Europe , Female , Follow-Up Studies , Humans , Internet , Israel , Male , Surveys and Questionnaires
18.
Inflamm Bowel Dis ; 10(4): 392-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15475747

ABSTRACT

In the literature there are indications of associations between health-related quality of life (HRQoL) in inflammatory bowel disease and disease activity, psychological status, coping, stressful life events, and social support. The aim of this study was to examine whether a relation exists between quality of health care and HRQoL, taking possible confounding variables into account. For this purpose, one single questionnaire was compiled from existing validated questionnaires. A population-based inception cohort of 1056 patients with inflammatory bowel disease in eight countries, diagnosed 6 to 8 years prior to the study, was approached to participate. In total, 824 patients responded (78%), and 517 could be included in statistical analyses. It was shown that in inflammatory bowel disease HRQoL was indeed influenced by quality of care (particularly with regard to the parameters of "providing information," "costs," and "courtesy"), as well as by disease activity, psychological status, type of hospital, social support, stressful life events, and way of administration of the questionnaire. Patients with active disease had lower psychological status and HRQoL scores at the time of the survey than patients without active disease. However, quality of care scores did not differ between these groups. The care aspect "costs" was scored worse by CD compared with UC patients, probably caused by a potentially more expensive treatment. In conclusion, it is shown in a large exploratory study, for the first time, that in inflammatory bowel disease, quality of care has a significant role in determining health-related quality of life.


Subject(s)
Inflammatory Bowel Diseases/pathology , Inflammatory Bowel Diseases/therapy , Quality of Health Care , Quality of Life , Adult , Cohort Studies , Female , Health Care Costs , Health Status , Humans , Inflammatory Bowel Diseases/psychology , Male , Middle Aged , Patient Education as Topic , Social Support , Stress, Psychological
19.
Eur J Gastroenterol Hepatol ; 16(9): 941-2, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15316423

ABSTRACT

Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. This proved to be extensive forearm deep venous thrombosis. The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case. With an increasing trend towards re-treating patients with known IIRs, clinicians should be aware of this potentially serious and previously unreported complication.


Subject(s)
Antibodies, Monoclonal/adverse effects , Drug Hypersensitivity/etiology , Forearm/blood supply , Gastrointestinal Agents/adverse effects , Venous Thrombosis/chemically induced , Adult , Crohn Disease/drug therapy , Female , Humans , Infliximab , Tumor Necrosis Factor-alpha/antagonists & inhibitors
20.
Digestion ; 69(4): 254-61, 2004.
Article in English | MEDLINE | ID: mdl-15256832

ABSTRACT

Quality of life is reduced in patients with irritable bowel syndrome, and the costs for this disease are substantial to society. During a meeting in London, UK, the IBiS club reviewed the literature on these subjects. Drawbacks and advantages with existing instruments to assess quality of life and costs were discussed and the clinical and scientific relevance of the current knowledge was assessed. A summary from the meeting is presented in this paper.


Subject(s)
Health Care Costs/statistics & numerical data , Irritable Bowel Syndrome/complications , Irritable Bowel Syndrome/economics , Quality of Life , Surveys and Questionnaires , Clinical Trials as Topic , Endpoint Determination , Humans , Irritable Bowel Syndrome/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...